<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378714</url>
  </required_header>
  <id_info>
    <org_study_id>STU00100303</org_study_id>
    <secondary_id>1R01CA184211-01A1</secondary_id>
    <nct_id>NCT02378714</nct_id>
  </id_info>
  <brief_title>Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers</brief_title>
  <official_title>Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persons who struggle with depression smoke at high rates and experience low quit rates in&#xD;
      treatment. The best way to improve cessation treatment for this underserved population&#xD;
      remains unknown. The proposed trial tests whether the combination of varenicline and&#xD;
      behavioral mood management treatment enhances long-term abstinence for depressed smokers and,&#xD;
      if so, whether this treatment achieves its effects through addressing the unique&#xD;
      psychological factors that appear to maintain tobacco dependence for these smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upwards of 43% of persons with major depressive disorder (MDD) are daily smokers who are more&#xD;
      likely to smoke heavily, show greater tobacco dependence, suffer more severe withdrawal, and&#xD;
      experience lower quit rates than smokers without MDD. Little is known about treatment&#xD;
      strategies that might optimize smoking cessation for smokers with MDD because almost all&#xD;
      randomized clinical trials have excluded these smokers. This project answers many prominent&#xD;
      but largely unanswered calls over the last decade to address tobacco dependence in persons&#xD;
      with mental health disorders, especially major depressive disorder (MDD). Using a&#xD;
      double-blind, placebo-controlled, randomized design, the investigators will evaluate the&#xD;
      efficacy of behavioral activation for smoking cessation (BASC) plus varenicline for treating&#xD;
      tobacco dependence in smokers with current or lifetime MDD. Three hundred and thirty daily&#xD;
      (≥1 cigarettes/day) smokers will be randomized to receive 12 weeks of one of four treatments:&#xD;
      1) Standard behavioral cessation treatment (ST) + placebo; 2) Behavioral activation&#xD;
      integrated with ST (BASC) + placebo; 3) ST + varenicline; or 4) BASC + varenicline. Both BASC&#xD;
      and ST will be administered in eight 45 minute sessions, occurring weekly for the first four&#xD;
      weeks and biweekly for the final eight weeks. Randomization will be stratified on clinical&#xD;
      site (Northwestern, University of Pennsylvania), gender, and severity of depressive symptoms&#xD;
      (minimal/mild vs. moderate/severe). The primary outcomes will be carbon monoxide (CO)&#xD;
      verified 7-day point prevalence abstinence at 24-weeks post-quit. Additional aims include&#xD;
      assessing adverse event rates between varenicline and placebo arms, and testing for mediation&#xD;
      of treatment effects by anhedonia, cognitive function (attention and memory), cigarette&#xD;
      reward value, and craving and withdrawal. This randomized controlled trial will be the first&#xD;
      adequately powered trial of BASC in this population; the first trial to evaluate varenicline&#xD;
      among a community sample of smokers with MDD; and the first trial to assess the main and&#xD;
      combined effects of these two treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2015</start_date>
  <completion_date type="Actual">March 13, 2020</completion_date>
  <primary_completion_date type="Actual">March 13, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioverified Point-prevalence Abstinence at 27 Weeks</measure>
    <time_frame>27 weeks (24-weeks post-target quit date)</time_frame>
    <description>Participants were classified as abstinent if they reported abstinence, not even a puff of a cigarette, for &gt;7 days prior to week 27 (24 weeks post-target quit date) and had an expired carbon monoxide reading of ≤ 6 parts per million at week 27.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event and Serious Adverse Event Rates</measure>
    <time_frame>Weeks 1 (1-week before starting medication), 6, and 14 (end of medication)</time_frame>
    <description>Adverse event and serious adverse event rates between varenicline and placebo arms. A previously developed algorithm was used to classify side effect reports as adverse events (AEs) or serious adverse events (SAEs) (Schnoll et al. 2019).&#xD;
Reference: Schnoll, R., Leone, F., Weisbrot, J., Veluz-Wilkins, A., Miele, A., Hole, A., Jao, N.C., Wileyto, E.P., Carroll, A.J., Kalhan, R., Patel, J., Langer, C., &amp; Hitsman, B. (2019). A randomized controlled trial of 24-weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence. Psycho-Oncology, 28, 561-569.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioverified Point-prevalence Abstinence at 14 Weeks (End of Treatment)</measure>
    <time_frame>14 weeks (11-weeks post-target quit date)</time_frame>
    <description>Participants were classified as abstinent if they reported abstinence, not even a puff of a cigarette, for &gt;7 days prior to week 14 (11-weeks post-target quit date) and had an expired carbon monoxide reading of ≤ 6 parts per million at week 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged Abstinence</measure>
    <time_frame>27 weeks (24 weeks post target quit date)</time_frame>
    <description>&lt;7 consecutive days of self-reported smoking after a 2-week grace period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Abstinence</measure>
    <time_frame>27 weeks (24 weeks post target quit date)</time_frame>
    <description>No smoking between target quit date (week 3) and week 27</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 7-day Relapse</measure>
    <time_frame>27 weeks (24 weeks post target quit date)</time_frame>
    <description>Time to relapse as defined by 7 or more consecutive days of self-reported smoking (no grace period)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Nicotine Dependence</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Standard treatment + placebo varenicline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard behavioral smoking cessation treatment plus placebo varenicline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BASC + placebo varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Behavioral activation for smoking cessation plus placebo varenicline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment + active varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard behavioral smoking cessation treatment plus active varenicline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BASC + active varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Behavioral activation for smoking cessation plus active varenicline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
    <arm_group_label>BASC + active varenicline</arm_group_label>
    <arm_group_label>Standard treatment + active varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>BASC</intervention_name>
    <description>The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
    <arm_group_label>BASC + active varenicline</arm_group_label>
    <arm_group_label>BASC + placebo varenicline</arm_group_label>
    <other_name>Behavioral activation for smoking cessation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
    <arm_group_label>Standard treatment + active varenicline</arm_group_label>
    <arm_group_label>Standard treatment + placebo varenicline</arm_group_label>
    <other_name>Standard Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. adult (18 years of age or older) daily cigarette smokers (1+ cigarettes per day)&#xD;
&#xD;
          2. meet criteria for current or lifetime MDD without psychotic features&#xD;
&#xD;
          3. have or are willing to acquire a personal email address and access to a camera phone&#xD;
             or other method for submission of therapy practice assignments&#xD;
&#xD;
          4. speak, read, and write fluently in English&#xD;
&#xD;
          5. able to provide written informed consent&#xD;
&#xD;
          6. intend to reside in the geographic area for &gt;8 months&#xD;
&#xD;
          7. women of childbearing potential must agree to use a medically acceptable method of&#xD;
             birth control or abstain from sexual intercourse during the time they are taking study&#xD;
             medication and for at least one month after the medication period ends.&#xD;
&#xD;
          8. The candidate had to answer &quot;yes&quot; to the question: &quot;Are you interested in quitting&#xD;
             smoking?&quot;&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. current enrollment or plan to enroll in another smoking cessation program in the next&#xD;
             8 months&#xD;
&#xD;
          2. regular (daily) use of e-cigarettes, chewing tobacco, snuff, snus, or other tobacco&#xD;
             products&#xD;
&#xD;
          3. current use or plan to use nicotine replacement therapy or other smoking cessation&#xD;
             medication within the next 8 months&#xD;
&#xD;
          4. medications indicated for bipolar or psychotic disorder if prescribed for bipolar or&#xD;
             psychotic disorder&#xD;
&#xD;
          5. pregnant or planning to become pregnant within the next 8 months, or breast feeding&#xD;
&#xD;
          6. history of seizures or current seizure disorder without medication&#xD;
&#xD;
          7. history of severe (stage IV or V) chronic kidney disease including current or prior&#xD;
             end stage renal disease on either hemodialysis or peritoneal dialysis or prior renal&#xD;
             transplant&#xD;
&#xD;
          8. any prior solid organ transplant or prior hematopoietic stem cell transplant&#xD;
&#xD;
          9. alcohol consumption exceeding 28 drinks per week&#xD;
&#xD;
         10. cirrhosis or end-stage liver disease&#xD;
&#xD;
         11. systolic blood pressure &gt;185 mmHg or diastolic blood pressure &gt;110 mmHg after two&#xD;
             readings or symptomatic uncontrolled stage II hypertension&#xD;
&#xD;
         12. unstable cardiovascular disease within 3 months prior to baseline or other&#xD;
             cardiovascular disease requiring hospitalization&#xD;
&#xD;
         13. prior hospitalization for heart failure&#xD;
&#xD;
         14. previous allergic reaction to varenicline&#xD;
&#xD;
         15. high suicide risk based on the Columbia Suicide Severity Rating Scale&#xD;
&#xD;
         16. lifetime bipolar or psychotic disorder as determined by either self-report or clinical&#xD;
             interview&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Hitsman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021928s012s013lbl.pdf</url>
    <description>FDA Product Information for Varenicline</description>
  </link>
  <reference>
    <citation>Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, Yunis C. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013 Sep 17;159(6):390-400. doi: 10.7326/0003-4819-159-6-201309170-00005. Erratum in: Ann Intern Med. 2013 Oct 15;159(8):576.</citation>
    <PMID>24042367</PMID>
  </reference>
  <reference>
    <citation>Blalock JA, Robinson JD, Wetter DW, Schreindorfer LS, Cinciripini PM. Nicotine withdrawal in smokers with current depressive disorders undergoing intensive smoking cessation treatment. Psychol Addict Behav. 2008 Mar;22(1):122-8. doi: 10.1037/0893-164X.22.1.122.</citation>
    <PMID>18298238</PMID>
  </reference>
  <reference>
    <citation>Ebbert JO, Wyatt KD, Hays JT, Klee EW, Hurt RD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence. 2010 Oct 5;4:355-62.</citation>
    <PMID>21049087</PMID>
  </reference>
  <reference>
    <citation>Gierisch JM, Bastian LA, Calhoun PS, McDuffie JR, Williams JW Jr. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. J Gen Intern Med. 2012 Mar;27(3):351-60. doi: 10.1007/s11606-011-1915-2. Epub 2011 Oct 26. Review.</citation>
    <PMID>22038468</PMID>
  </reference>
  <reference>
    <citation>Hitsman B, Moss TG, Montoya ID, George TP. Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry. 2009 Jun;54(6):368-78. Review.</citation>
    <PMID>19527557</PMID>
  </reference>
  <reference>
    <citation>Hitsman B, Papandonatos GD, McChargue DE, DeMott A, Herrera MJ, Spring B, Borrelli B, Niaura R. Past major depression and smoking cessation outcome: a systematic review and meta-analysis update. Addiction. 2013 Feb;108(2):294-306. doi: 10.1111/add.12009. Review.</citation>
    <PMID>23072580</PMID>
  </reference>
  <reference>
    <citation>Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry. 2009 Jul;70(7):1026-31. Epub 2009 Mar 24.</citation>
    <PMID>19323966</PMID>
  </reference>
  <reference>
    <citation>MacPherson L, Tull MT, Matusiewicz AK, Rodman S, Strong DR, Kahler CW, Hopko DR, Zvolensky MJ, Brown RA, Lejuez CW. Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms. J Consult Clin Psychol. 2010 Feb;78(1):55-61. doi: 10.1037/a0017939.</citation>
    <PMID>20099950</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <results_first_submitted>March 13, 2021</results_first_submitted>
  <results_first_submitted_qc>May 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 27, 2021</results_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Brian Hitsman</investigator_full_name>
    <investigator_title>Associate Professor of Preventive Medicine</investigator_title>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Nicotine Dependence</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Behavioral Activation Therapy</keyword>
  <keyword>Cigarette Smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02378714/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02378714/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Treatment + Placebo Varenicline</title>
          <description>Standard behavioral smoking cessation treatment plus placebo varenicline&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
        </group>
        <group group_id="P2">
          <title>BASC + Placebo Varenicline</title>
          <description>Behavioral activation for smoking cessation plus placebo varenicline&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
        </group>
        <group group_id="P3">
          <title>Standard Treatment + Active Varenicline</title>
          <description>Standard behavioral smoking cessation treatment plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
        </group>
        <group group_id="P4">
          <title>BASC + Active Varenicline</title>
          <description>Behavioral activation for smoking cessation plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Treatment + Placebo Varenicline</title>
          <description>Standard behavioral smoking cessation treatment plus placebo varenicline&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
        </group>
        <group group_id="B2">
          <title>BASC + Placebo Varenicline</title>
          <description>Behavioral activation for smoking cessation plus placebo varenicline&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
        </group>
        <group group_id="B3">
          <title>Standard Treatment + Active Varenicline</title>
          <description>Standard behavioral smoking cessation treatment plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
        </group>
        <group group_id="B4">
          <title>BASC + Active Varenicline</title>
          <description>Behavioral activation for smoking cessation plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="83"/>
            <count group_id="B5" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="270"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="10.8"/>
                    <measurement group_id="B2" value="50.7" spread="13.5"/>
                    <measurement group_id="B3" value="48.7" spread="12.7"/>
                    <measurement group_id="B4" value="50.3" spread="13.2"/>
                    <measurement group_id="B5" value="50.0" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioverified Point-prevalence Abstinence at 27 Weeks</title>
        <description>Participants were classified as abstinent if they reported abstinence, not even a puff of a cigarette, for &gt;7 days prior to week 27 (24 weeks post-target quit date) and had an expired carbon monoxide reading of ≤ 6 parts per million at week 27.</description>
        <time_frame>27 weeks (24-weeks post-target quit date)</time_frame>
        <population>All participants enrolled in the trial (intent-to-treat sample)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment + Placebo Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus placebo varenicline&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O2">
            <title>BASC + Placebo Varenicline</title>
            <description>Behavioral activation for smoking cessation plus placebo varenicline&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O3">
            <title>Standard Treatment + Active Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O4">
            <title>BASC + Active Varenicline</title>
            <description>Behavioral activation for smoking cessation plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioverified Point-prevalence Abstinence at 27 Weeks</title>
          <description>Participants were classified as abstinent if they reported abstinence, not even a puff of a cigarette, for &gt;7 days prior to week 27 (24 weeks post-target quit date) and had an expired carbon monoxide reading of ≤ 6 parts per million at week 27.</description>
          <population>All participants enrolled in the trial (intent-to-treat sample)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Event and Serious Adverse Event Rates</title>
        <description>Adverse event and serious adverse event rates between varenicline and placebo arms. A previously developed algorithm was used to classify side effect reports as adverse events (AEs) or serious adverse events (SAEs) (Schnoll et al. 2019).&#xD;
Reference: Schnoll, R., Leone, F., Weisbrot, J., Veluz-Wilkins, A., Miele, A., Hole, A., Jao, N.C., Wileyto, E.P., Carroll, A.J., Kalhan, R., Patel, J., Langer, C., &amp; Hitsman, B. (2019). A randomized controlled trial of 24-weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence. Psycho-Oncology, 28, 561-569.</description>
        <time_frame>Weeks 1 (1-week before starting medication), 6, and 14 (end of medication)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Week 1</title>
            <description>Placebo group during first week of treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline - Week 1</title>
            <description>Varenicline group during first week of treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Week 6</title>
            <description>Placebo group mid-treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
          </group>
          <group group_id="O4">
            <title>Varenicline - Week 6</title>
            <description>Placebo group mid-treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
          </group>
          <group group_id="O5">
            <title>Placebo - Week 14</title>
            <description>Placebo group at end of treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
          </group>
          <group group_id="O6">
            <title>Varenicline - Week 14</title>
            <description>Placebo group at end of treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event and Serious Adverse Event Rates</title>
          <description>Adverse event and serious adverse event rates between varenicline and placebo arms. A previously developed algorithm was used to classify side effect reports as adverse events (AEs) or serious adverse events (SAEs) (Schnoll et al. 2019).&#xD;
Reference: Schnoll, R., Leone, F., Weisbrot, J., Veluz-Wilkins, A., Miele, A., Hole, A., Jao, N.C., Wileyto, E.P., Carroll, A.J., Kalhan, R., Patel, J., Langer, C., &amp; Hitsman, B. (2019). A randomized controlled trial of 24-weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence. Psycho-Oncology, 28, 561-569.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bioverified Point-prevalence Abstinence at 14 Weeks (End of Treatment)</title>
        <description>Participants were classified as abstinent if they reported abstinence, not even a puff of a cigarette, for &gt;7 days prior to week 14 (11-weeks post-target quit date) and had an expired carbon monoxide reading of ≤ 6 parts per million at week 14.</description>
        <time_frame>14 weeks (11-weeks post-target quit date)</time_frame>
        <population>All participants enrolled in the trial (intent-to-treat sample)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment + Placebo Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus placebo varenicline&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O2">
            <title>BASC + Placebo Varenicline</title>
            <description>Behavioral activation for smoking cessation plus placebo varenicline&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O3">
            <title>Standard Treatment + Active Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O4">
            <title>BASC + Active Varenicline</title>
            <description>Behavioral activation for smoking cessation plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioverified Point-prevalence Abstinence at 14 Weeks (End of Treatment)</title>
          <description>Participants were classified as abstinent if they reported abstinence, not even a puff of a cigarette, for &gt;7 days prior to week 14 (11-weeks post-target quit date) and had an expired carbon monoxide reading of ≤ 6 parts per million at week 14.</description>
          <population>All participants enrolled in the trial (intent-to-treat sample)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prolonged Abstinence</title>
        <description>&lt;7 consecutive days of self-reported smoking after a 2-week grace period</description>
        <time_frame>27 weeks (24 weeks post target quit date)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment + Placebo Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus placebo varenicline&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O2">
            <title>BASC + Placebo Varenicline</title>
            <description>Behavioral activation for smoking cessation plus placebo varenicline&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O3">
            <title>Standard Treatment + Active Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O4">
            <title>BASC + Active Varenicline</title>
            <description>Behavioral activation for smoking cessation plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
        </group_list>
        <measure>
          <title>Prolonged Abstinence</title>
          <description>&lt;7 consecutive days of self-reported smoking after a 2-week grace period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Abstinence</title>
        <description>No smoking between target quit date (week 3) and week 27</description>
        <time_frame>27 weeks (24 weeks post target quit date)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment + Placebo Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus placebo varenicline&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O2">
            <title>BASC + Placebo Varenicline</title>
            <description>Behavioral activation for smoking cessation plus placebo varenicline&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O3">
            <title>Standard Treatment + Active Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O4">
            <title>BASC + Active Varenicline</title>
            <description>Behavioral activation for smoking cessation plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Abstinence</title>
          <description>No smoking between target quit date (week 3) and week 27</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 7-day Relapse</title>
        <description>Time to relapse as defined by 7 or more consecutive days of self-reported smoking (no grace period)</description>
        <time_frame>27 weeks (24 weeks post target quit date)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Treatment + Placebo Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus placebo varenicline&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O2">
            <title>BASC + Placebo Varenicline</title>
            <description>Behavioral activation for smoking cessation plus placebo varenicline&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O3">
            <title>Standard Treatment + Active Varenicline</title>
            <description>Standard behavioral smoking cessation treatment plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
Standard treatment: Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
          <group group_id="O4">
            <title>BASC + Active Varenicline</title>
            <description>Behavioral activation for smoking cessation plus active varenicline&#xD;
Varenicline: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.&#xD;
BASC: The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.&#xD;
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 7-day Relapse</title>
          <description>Time to relapse as defined by 7 or more consecutive days of self-reported smoking (no grace period)</description>
          <units>median days to relapse</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="15" upper_limit="16"/>
                    <measurement group_id="O2" value="15" lower_limit="15" upper_limit="22"/>
                    <measurement group_id="O3" value="57" lower_limit="15" upper_limit="144"/>
                    <measurement group_id="O4" value="24" lower_limit="15" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Medication side effects were measured using a 28-item side effect checklist rating scale at week 1 (1 week before starting medication), week 3 (target quit day) through 14, and week 27.</time_frame>
      <desc>Adverse events and serious adverse events are reported only for active and placebo medication arms, which aligns with our primary aim for varenicline safety and the statistical analysis plan.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Week 1</title>
          <description>Placebo group during first week of treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E2">
          <title>Varenicline - Week 1</title>
          <description>Varenicline group during first week of treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E3">
          <title>Placebo - Week 3</title>
          <description>Placebo group at week 3.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E4">
          <title>Varenicline - Week 3</title>
          <description>Varenicline group at week 3.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E5">
          <title>Placebo - Week 4</title>
          <description>Placebo group at week 4.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E6">
          <title>Varenicline - Week 4</title>
          <description>Varenicline group at week 4.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E7">
          <title>Placebo - Week 6</title>
          <description>Placebo group mid-treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E8">
          <title>Varenicline - Week 6</title>
          <description>Varenicline group mid-treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E9">
          <title>Placebo - Week 7</title>
          <description>Placebo group at week 7.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E10">
          <title>Varenicline - Week 7</title>
          <description>Varenicline group at week 7.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E11">
          <title>Placebo - Week 8</title>
          <description>Placebo group at week 8.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E12">
          <title>Varenicline - Week 8</title>
          <description>Varenicline group at week 8.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E13">
          <title>Placebo - Week 10</title>
          <description>Placebo group at week 10.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E14">
          <title>Varenicline - Week 10</title>
          <description>Varenicline group at week 10.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E15">
          <title>Placebo - Week 12</title>
          <description>Placebo group at week 12.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E16">
          <title>Varenicline - Week 12</title>
          <description>Varenicline group at week 12.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E17">
          <title>Placebo - Week 14</title>
          <description>Placebo group at end of treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E18">
          <title>Varenicline - Week 14</title>
          <description>Varenicline group at end of treatment.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E19">
          <title>Placebo - Week 27</title>
          <description>Placebo group at week 27.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
        <group group_id="E20">
          <title>Varenicline - Week 27</title>
          <description>Varenicline group at week 27.&#xD;
Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally&#xD;
Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="12" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular heartbeat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Increased heart rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Skin swelling or rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>skin redness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Weakness on one or both sides of the body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Suicidal thoughts or i deation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="103" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="80" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="93" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="68" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="81" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="65" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="77" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="57" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="71" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="51" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="71" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="52" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="63" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="50" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="60" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="37" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="55" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular Heartbeat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Increased heart rate or palpitations</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="21" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="21" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="15" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="17" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Increased Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux or indigestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Skin swelling or rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fatigue/lethargy</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Feeling of weakness without loss of strength</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Skin redness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Weakness on one or both sides of the body</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="9" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep problems</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="21" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="22" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="14" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="15" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="42" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="39" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="42" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="41" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="39" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="33" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="31" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="30" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="33" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="32" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="27" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="25" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="30" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="28" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="21" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="24" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="17" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="20" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="19" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="21" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="14" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="20" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="121"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="119"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E13" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E14" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E15" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E16" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E17" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E18" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E19" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E20" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brian Hitsman</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-504-5834</phone>
      <email>b-hitsman@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

